Cargando…
Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study
SIMPLE SUMMARY: FOLFIRINOX, which is a first-line chemotherapy for metastatic pancreatic cancer, has become one of the high-risk regimens related to developing febrile neutropenia (FN). Although UGT1A1 polymorphisms are associated with the metabolism of irinotecan, their role as surrogate markers fo...
Autores principales: | Keum, Jiyoung, Lee, Hee Seung, Jo, Jung Hyun, Chung, Moon Jae, Park, Jeong Youp, Park, Seung Woo, Song, Si Young, Bang, Seungmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909027/ https://www.ncbi.nlm.nih.gov/pubmed/35267552 http://dx.doi.org/10.3390/cancers14051244 |
Ejemplares similares
-
BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
por: Park, Ji Hoon, et al.
Publicado: (2022) -
Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer
por: Kang, Huapyong, et al.
Publicado: (2018) -
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020) -
Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
por: Shirasu, Hiromichi, et al.
Publicado: (2018) -
Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial
por: Keum, Jiyoung, et al.
Publicado: (2021)